CClinicalTrials.gg
TerminatedNCT03555981eKMCUpdated Apr 16, 2026Results posted

Early Kangaroo Mother Care in Gambian Hospitalised Unstable Neonates

An interventional study of Early Kangaroo Mother Care and Standard care in Preterm Infant, Hypothermia, Newborn and Death, sponsored by London School of Hygiene and Tropical Medicine. Terminated at 1 site in The Gambia. Open to participants aged 1 Hour to 24 Hours. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by London School of Hygiene and Tropical Medicine · Not applicable, Interventional, and Treatment

Why this study was terminated
In response to COVID pandemic
Phase
Not applicable
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
1 Hour to 24 Hours
Sex
All
01

Study summary

The mortality effect of kangaroo mother care in stable newborns \<2000g is well established but mortality effect in unstable newborns is not conclusively known. This pragmatic clinical trial aims to investigate the mortality and clinical effects of early continuous Kangaroo Mother Care (KMC) compared to standard care in mild-moderately unstable neonates \<2000g in a resource limited hospital setting.

Read the detailed description

This individually randomised controlled trial will compare 2 parallel groups of hospitalised mild-moderately unstable neonates \<2000g and aged \<24h at time of screening who receive either early continuous kangaroo mother care (KMC) (started at \<24h of admission) or standard care with continuous KMC at >24h of admission and when stable. The intervention will be un-blinded to participants and researchers with blinding of outcomes where possible. If participants clinically deteriorate and meet "stopping criteria" they will be temporarily withdrawn from the intervention arm and re-start KMC when clinically stable, as per the control arm. Intention to treat analysis will be used. Duration of time spent in KMC will be documented and compared between arms. All other hospital management will be provided as per a Standardised Preterm Management Protocol, based on current standard care at the study site and compliance to this protocol will be monitored in both arms.

Underlying protective mechanisms for early KMC will also be explored, focusing on causal pathways such as thermal control, cardio-respiratory stability, infection prevention control and gastro-intestinal stability pathways.

02

Conditions studied

  • Preterm Infant
  • Hypothermia, Newborn
  • Death
  • Kangaroo Mother Care
  • Infection, Bacterial
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's enrollment of 279 is above the median of 84 across 1,689 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

London School of Hygiene and Tropical Medicine is the lead sponsor of 296 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Hour to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • New admission to study site during study period
  • Admission weight \<2000g
  • Age 1 - 24h at start of screening
  • Alive at enrolment
  • Availability of study bed
  • Written informed consent from parent or caregiver
  • Parent or caregiver available and willing to provide intervention, if necessary

Exclusion criteria

Exclusion Criteria:

  • Congenital malformation incompatible with life or needing immediate surgical correction
  • Severe jaundice needing immediate management
  • Seizures
  • Clinically stable as assessed over pre-defined period of cardio-respiratory monitoring
  • Severely unstable as assessed over pre-defined period of cardio-respiratory monitoring
  • Completed triplet admission
  • Mother and/or neonate enrolled in another research study at time of hospital admission
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Early KMC

    Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home

    Other: Early Kangaroo Mother Care

  • Active comparator
    Standard care

    Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at \>24h of hospital admission until hospital discharge with encouragement of KMC at home

    Other: Standard care

Interventions

  • OtherEarly Kangaroo Mother Care

    Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission

    Also known as: Early skin-to-skin contact, Early kangaroo method

  • OtherStandard care

    Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care

06

What researchers measure

Primary outcomes

  1. All-cause Mortality

    All neonatal deaths within 28 postnatal days

    Time frame: 28 days

Secondary outcomes

  1. Time to Death

    Time from start of intervention/control procedures to death

    Time frame: 28 days of age

  2. Cardio-respiratory Stability

    The 'Stability of Cardio-Respiratory in Preterm' infants is a scale to quantify the cardio-respiratory stability of preterm infants. It is composed of three parameters: Heart rate; Respiratory rate and breathing pattern and oxygen saturation (including whether is in oxygen). Scores between 0 and 2 are allocated for each parameter, with minimum total score 0 and maximum total score 6. The highest score (6) represents a better outcome, with all parameters within normal range whilst not receiving oxygen.

    Time frame: At 24 hours after start of intervention/control procedures

  3. Number and Proportion of Participants With Hypothermia

    Number and proportion of participants with hypothermia (Temperature \<36.5 degrees Celsius)

    Time frame: At 24 hours after start of intervention/control procedures

  4. Weight Gain

    Average daily weight gain compared to admission weight

    Time frame: At 28 days of age

  5. Exclusive Breastfeeding

    Number of babies who are exclusively breastfed (defined as only receiving breast milk with no infant formula supplementation)

    Time frame: At time of hospital discharge, within study period, on average 2 weeks of age

  6. Suspected Infection Between 3d to 28d of Age

    Number and proportion of participants with suspected infection between 3d to 28d of age, or age at latest follow up

    Time frame: Within 28 days of age

  7. Neonatal Intestinal Carriage of Extended Spectrum Beta-Lactamase-producing Klebsiella Pneumoniae

    Number and proportion of participants with intestinal carriage of Extended Spectrum Beta-Lactamase-Klebsiella pneumoniae

    Time frame: At day 28 of age

  8. Duration of Hospital Admission

    Mean length of admission (first admission only if re-admitted)

    Time frame: Within 28 days of age or at latest follow-up

07

Results

Posted Oct 16, 2023

Participant flow

Recruitment took place from 23rd May 2018 - 19th March 2020 at the neonatal unit of the only teaching hospital in The Gambia, providing WHO level 2+ newborn care.

Participant flow — Overall Study
MilestoneEarly KMCStandard Care
Started138141
Completed138139
Not completed02
Withdrew: Lost to follow-up02

Outcome measures

PrimaryAll-cause Mortality

All neonatal deaths within 28 postnatal days

Time frame:
28 days
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsEarly KMCStandard Care
All-cause Mortality2934
SecondaryTime to Death

Time from start of intervention/control procedures to death

Time frame:
28 days of age
Reported as:
Median · hours
Time to Death
hoursEarly KMCStandard Care
Time to Death90.0 (65 to 172)98.5 (29 to 132)
SecondaryCardio-respiratory Stability

The 'Stability of Cardio-Respiratory in Preterm' infants is a scale to quantify the cardio-respiratory stability of preterm infants. It is composed of three parameters: Heart rate; Respiratory rate and breathing pattern and oxygen saturation (including whether is in oxygen). Scores between 0 and 2 are allocated for each parameter, with minimum total score 0 and maximum total score 6. The highest score (6) represents a better outcome, with all parameters within normal range whilst not receiving oxygen.

Time frame:
At 24 hours after start of intervention/control procedures
Reported as:
Median · units on a scale
Cardio-respiratory Stability
units on a scaleEarly KMCStandard Care
Cardio-respiratory Stability5 (4 to 5)5 (4 to 6)
SecondaryNumber and Proportion of Participants With Hypothermia

Number and proportion of participants with hypothermia (Temperature \<36.5 degrees Celsius)

Time frame:
At 24 hours after start of intervention/control procedures
Reported as:
Count of participants · Participants
Number and Proportion of Participants With Hypothermia
ParticipantsEarly KMCStandard Care
Number and Proportion of Participants With Hypothermia5155
SecondaryWeight Gain

Average daily weight gain compared to admission weight

Time frame:
At 28 days of age
Reported as:
Mean · grams/day
Weight Gain
grams/dayEarly KMCStandard Care
Weight Gain10.3 ± 10.112.5 ± 12.1
SecondaryExclusive Breastfeeding

Number of babies who are exclusively breastfed (defined as only receiving breast milk with no infant formula supplementation)

Time frame:
At time of hospital discharge, within study period, on average 2 weeks of age
Reported as:
Count of participants · Participants
Exclusive Breastfeeding
ParticipantsEarly KMCStandard Care
Exclusive Breastfeeding107105
SecondarySuspected Infection Between 3d to 28d of Age

Number and proportion of participants with suspected infection between 3d to 28d of age, or age at latest follow up

Time frame:
Within 28 days of age
Reported as:
Count of participants · Participants
Suspected Infection Between 3d to 28d of Age
ParticipantsEarly KMCStandard Care
Suspected Infection Between 3d to 28d of Age2821
SecondaryNeonatal Intestinal Carriage of Extended Spectrum Beta-Lactamase-producing Klebsiella Pneumoniae

Number and proportion of participants with intestinal carriage of Extended Spectrum Beta-Lactamase-Klebsiella pneumoniae

Time frame:
At day 28 of age

Results for this outcome have not been posted.

SecondaryDuration of Hospital Admission

Mean length of admission (first admission only if re-admitted)

Time frame:
Within 28 days of age or at latest follow-up
Reported as:
Mean · Days
Duration of Hospital Admission
DaysEarly KMCStandard Care
Duration of Hospital Admission16.6 ± 11.116.3 ± 10.0

Adverse events

Collected over 28 postnatal days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early KMC29/138 (21%)30/138 (21.7%)—
Standard Care34/141 (24.1%)28/141 (19.9%)—
Most frequent serious events
Most frequent serious events
EventEarly KMCStandard Care
Life threatening eventGeneral disorders13/13811/141
Prolonged hospitalisationGeneral disorders7/1385/141
Risk of disabilityNervous system disorders6/1387/141
Hospital re-admissionGeneral disorders4/1385/141

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Early KMCStandard CareTotal
<=18 years138141279
Between 18 and 65 yearsNANANA
>=65 yearsNANANA
Age, Continuous
Age, Continuous(hours)Early KMCStandard CareTotal
Median2.3 (0.9 to 4.7)2.3 (0.7 to 5.0)2.3 (0.8 to 4.8)
Sex: Female, Male
Sex: Female, Male(Participants)Early KMCStandard CareTotal
Female7982161
Male5959118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Early KMCStandard CareTotal
Gambian138141279
Region of Enrollment
Region of Enrollment(participants)Early KMCStandard CareTotal
Gambia138141279
Admission weight
Admission weight(grams)Early KMCStandard CareTotal
Median1459 (1204 to 1650)1436 (1180 to 1660)1450 (1180 to 1652)
Admission weight <1200g
Admission weight <1200g(Participants)Early KMCStandard CareTotal
Count of participants343973
Gestational age
Gestational age(weeks)Early KMCStandard CareTotal
Median33 (31 to 34)32 (31 to 34)33 (31 to 34)

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • MRC Unit The Gambia at LSHTM
    Fajara, West Coast, The Gambia
09

References and documents

Publications

  • Brotherton H, Gai A, Kebbeh B, Njie Y, Walker G, Muhammad AK, Darboe S, Jallow M, Ceesay B, Samateh AL, Tann CJ, Cousens S, Roca A, Lawn JE. Impact of early kangaroo mother care versus standard care on survival of mild-moderately unstable neonates <2000 grams: A randomised controlled trial. EClinicalMedicine. 2021 Aug 6;39:101050. doi: 10.1016/j.eclinm.2021.101050. eCollection 2021 Sep. PubMed 34401686 ↗
  • Brotherton H, Gai A, Tann CJ, Samateh AL, Seale AC, Zaman SMA, Cousens S, Roca A, Lawn JE. Protocol for a randomised trial of early kangaroo mother care compared to standard care on survival of pre-stabilised preterm neonates in The Gambia (eKMC). Trials. 2020 Mar 6;21(1):247. doi: 10.1186/s13063-020-4149-y. PubMed 32143737 ↗

Study documents

  • Study protocol · Mar 18, 2018
  • Statistical analysis plan · Jun 24, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03555981
Lead sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Wellcome Trust, Medical Research Council Unit, The Gambia
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
May 20, 2018
Primary completion
Apr 20, 2020
Completion
Apr 20, 2020
Results posted
Oct 16, 2023
Last update
Apr 16, 2026

Study contacts

Helen C Brotherton, MBChB
principal investigator · London School of Hygiene and Tropical Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion